Archived explainer. For the current picture see today's JNJ page.
JOHNSON & JOHNSON (JNJ) is drawing unusual attention today. Our newswire has captured 11 stories on JNJ across 8 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Johnson & Johnson (JNJ) stock is moving higher today as the company received U.S. Food and Drug Administration authorization for its Ottava robotic surgical system. The approval marks a milestone in the company’s expansion into robotic surgery and has driven the stock up more than 2.2% as of the latest trade. The Ottava system is the first table-integrated soft-tissue robotic surgical system authorized for multiple general surgery procedures, including gastric bypass and appendectomy.
The FDA granted De Novo authorization for the Ottava robotic surgical system, a development that has positioned Johnson & Johnson as a key player in the next phase of robotic-assisted surgery. The Ottava system is designed to offer improved precision and flexibility in general surgery. The company plans to commercially launch the system with select U.S. customers while pursuing additional indications. Analysts from Guggenheim and Raymond James have reiterated or raised their price targets for JNJ in recent weeks, signaling confidence in the company’s long-term potential.
The stock opened at $252.22, up 0.6% from the previous close, and reached an intraday high of $256.29 before settling at $255.79. Trading volume has been muted at 1.6 million shares, or 20% of the 3-month daily average. Over the past eight sessions, the stock has declined 1.1% from $257.90 to $255.12. The stock is currently trading within its 52-week range of $162.78 to $269.43. Additionally, the stock printed one notable options trade, a call premium of $425,000, with no put activity recorded.
Johnson & Johnson is scheduled to report first-quarter 2026 earnings on July 24. Analysts are forecasting adjusted earnings per share of $2.69 and revenue of $23.66 billion. The company’s recent insider and congressional transactions, as well as the broader healthcare sector’s performance, will also be key factors to monitor.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Shares in medical group Johnson Johnson ($JNJ) were healthier today after it received the green light to begin the “next era” of robotic surgery. Robotic Oper...
Shares of Johnson Johnson ($JNJ) are marching higher after the healthcare company’s robotic surgery device was approved by the U.S. Food and Drug Administrati...
J&J on Wednesday said the FDA green light covers Ottava, the world's first table-integrated soft-tissue robotic system, for multiple procedures in general surgery, including gastric bypass, gastric sleeve, small-bowel resection, appendectomy and hiatal-hernia repair.
Johnson & Johnson (JNJ) wins FDA's De Novo authorization for the company’s soft tissue robotic system, Ottava. Read more here.
Gastric bypass, appendectomy and other procedures are covered; J&J will commercially launch OTTAVA with select U.S. customers while advancing additional indications.
Investors looking for steady cash payments can bank on NextEra ($NEE), Coca-Cola ($KO), and Johnson Johnson ($JNJ). Top analysts covering these stocks say the...
JNJ is pruning its portfolio while Abbott just dropped $21 billion to expand into cancer diagnostics, and the two strategies are pulling their stocks in completely opposite directions. Which move looks smarter when you dig into the actual earnings?
More on JNJ: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier JNJ move explainers: 2026-07-22 · 2026-07-21 · 2026-07-14